OCT has been awarded with 6 local studies for a global pharmaceutical company. OCT will provide full service to the client. OCT will provide medical writing, project management, clinical monitoring, data management and statistics to the client. OCT will perform 1 bioavalability study for a mucoactive drug, 1 bioequivalence study for an anti-inflammatory drug and 4 phase III studies for an antispasmodic drug, muscles and joint pain drug, obstructive respiratory tract diseases drug and thrombolytic drug. OCT President, Dmitry Sharov, commented “These studies are highly important studies and OCT will do our best to provide services on time. We will use our knowledge and experience to support drug registration studies for these drugs in Russia. We also want the client to consider us as a strategic partner in Russia”. Our flexible team structure allows us to ramp up resource quickly for these projects to meet the specific needs of our sponsor and start these trials as soon as possible.